share_log

Guggenheim Initiates Coverage On 10x Genomics With Buy Rating, Announces Price Target of $60

Benzinga ·  Dec 14, 2023 05:59

Guggenheim analyst Subbu Nambi initiates coverage on 10x Genomics (NASDAQ:TXG) with a Buy rating and announces Price Target of $60.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment